Related News

No related news articles were found.

theralase technologies inc (TLT) Related Businessweek News

No Related Businessweek News Found

theralase technologies inc (TLT) Details

Theralase Technologies Inc. designs, develops, manufactures, and markets laser technology used in bio-stimulative and bio-destructive clinical applications. The company engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of chronic pain, neural muscular-skeletal conditions, and wound healing. It is also involved in the commercialization of the patented TLC-3000 photo dynamic compound technology through pre-clinical scientific research, clinical trials, and technology development in the treatment of cancers for oncological applications and in the destruction of bacteria, viruses, and microbial pathogens; and research and development activities. The company sells its products to licensed healthcare practitioners, such as medical doctors, chiropractors, physical therapists, and athletic therapists in Canada, the United States, and internationally. Theralase Technologies Inc. is headquartered in Toronto, Canada.

theralase technologies inc (TLT) Key Developments

Theralase Technologies Inc. Identifies Potential Mechanism of How Lead Anti-Cancer Drug Works to Destroy Cancer and Discovers New Application to Detect Cancer Cells

Feb 23 15

Theralase Technologies Inc. announced that it has identified a potential mechanism of how its lead anti-cancer drug works to destroy cancer cells and has also discovered a new application of the lead drug that may lead to the ability to detect the presence of cancer cells. Theralase's lead Photo Dynamic Compound TLD-1433, when combined with transferrin (a naturally occurring iron-binding blood plasma glycoprotein found in its body), was recently described in the provisional U.S patent application, entitled, Transferrin Enhanced Photo Dynamic Therapy Cancer Destruction. Theralase's Ruthenium based PDC TLD-1433 combined with transferrin has now been branded and trademarked by the Company, as Rutherrin. Rutherrin has demonstrated an ability to significantly increase the targeting of bladder cancer cells and in the process, significantly increase the efficacy and safety of the treatment procedure. TLD-1433 is able to bind to transferrin to form Rutherrin as evident from the change in absorption spectra in the chart below. These findings support the preferential uptake of Rutherrin (transferrin-bound TLD-1433) by cancer cells that are known to have an increased number of transferrin receptors. Rutherrin allows TLD-1433 to uptake faster and in larger quantities into rat bladder cancer cells (AY27) than without transferrin by 300%. These photos also demonstrate that Rutherin is not located in the nuclei of the cell, but localizes into the cytoplasm of the cancer cell, potentially at the mitochondria. Thus how TLD-1433 and Rutherrin work is by localization into the As an added advantage, both TLD-1433 and Rutherrin may be used as tools to detect cancer cells through fluorescence. The fluorescent signature has been even further enhanced by the introduction of transferrin. Fluorescent micrograph images of rat cancer cells (AY27) with TLD-1433 alone and when combined with transferrin to produce Rutherrin demonstrate the fluorescent signature. In 2015, Theralase will execute on two strategic objectives aimed at increasing long term shareholder value in both Therapeutic Laser Technology and Photo Dynamic Therapy divisions; specifically: the launch of next generation TLC-2000 therapeutic laser with Cell Sensing technology that provides higher efficacy than any other therapeutic laser on the market and the commencement of Health Canada /FDA Phase I /II a clinical trial in humans for Non Muscle Invasive Bladder Cancer aimed at the destruction of bladder cancer.

Theralase Technologies Inc. announced that research on its Anti-Cancer Technology platform involving its lead Photo Dynamic Compound TLD-1433 has shown that it has significantly less skin toxicity than the Food and Drug Administration approved PDC Photofrin. Photofrin has been documented to induce skin sensitivity in patient's treated with the PDC to sunlight or bright lights after administration. Patients who receive Photofrin will be photosensitive and must strictly avoid exposure of skin and eyes to direct sunlight or bright indoor light (examination lamps, dental lamps, operating room lamps, un shaded light bulbs at close proximity, etc.) for at least 30 days post treatment. Some patients may remain photosensitive for up to 90 days or more. The photosensitivity is due to residual traces of the drug, which will be present in all parts of the skin. This necessitates the patient to stay indoors after treatment to prevent potential skin damage. Theralase employed a mouse model and Inductively Coupled Plasma Mass Spectrometry to measure the levels of TLD-1433 in skin following systemic administration (worst-case scenario). Previously published mathematical models were then used to compare the sensitivity of skin containing TLD-1433 to Photofrin. TLD-1433 produced 10,000,000 times less Reactive Oxygen Species in the skin than Photofrin; therefore, providing a much higher safety margin to light sensitivity than Photofrin allowing patients the opportunity post treatment to enter direct sunlight within days and not months. This latest research adds more support to the high safety profile of the lead drug candidate TLD-1433 and its ability to minimize one of the reported side effects of PDT by a FDA approved PDC. Theralase plans to commence clinical evaluation of TLD-1433 in Non Muscle Invasive Bladder Cancer in mid 2015.

Theralase's Latest Research on Anti-Cancer Technology Accepted for Presentation at International Conference

Jan 29 15

Theralase Technologies Inc. announced that its latest research on its lead Photo Dynamic Compound ("PDC") TLD-1433 binding to transferrin has been accepted for presentation at the 15th International Photodynamic Association (IPA) /Society of Photo-Optical Instrumentation Engineers ("SPIE") Biophotonics Conference taking place in Rio de Janeiro, Brazil from May 22 to 26, 2015. The scientific data pertaining to Theralase's discovery that Ruthenium based medicine, including TLD-1433, are enhanced in their physical characteristics upon binding to transferrin has been peer reviewed and selected for presentation. Overexpression of transferrin receptors ("TfR") for a variety of cancers has been scientifically documented and is attributed to the malignant transformation of normal cells into cancer cells. Theralase's recent scientific research has demonstrated that Theralase's lead PDC, TLD-1433, when combined with human transferrin, dramatically increases the targeting mechanism of TLD-1433 towards cells overexpressing TfR, primarily cancer cells; hence, further increasing the efficacy and safety of TLD-1433 in destroying these cancer cells. Theralase's latest scientific research has shown that TLD-1433 directly bound to transferrin results in significant enhancements of TLD1433's biomedical properties and its efficacy in the destruction of cancer cells: More than doubles the maximum tolerated dose of TLD-1433 (greater payloads of TLD-1433 to cancer cells and thus higher efficacy); Photobleaching (loss of efficacy) resistance and reactive oxygen species (PDC potency) production are both increased resulting in longer photoactivation of the PDC and higher efficacy due to an improved therapeutic ratio (increased cancer cell kill); Increased absorption in green light resulting in higher efficacy and new absorption in the red and Near Infra Red ("NIR") wavelengths (greater efficacy at increasing tissue depths with an ability to destroy deeper tumours); and reduced dark toxicity (cell kill in the absence of light activation) resulting in higher margins of safety for healthy tissues (higher therapeutic ratio).

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.